X0202 4 2006-09-12 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001239241 EVNIN ANTHONY B C/O VENROCK ASSOCIATES 30 ROCKEFELLER PLAZA, ROOM 5508 NEW YORK NY 10112 1 0 0 0 Common Stock 2006-09-12 4 A 0 91736 A 91736 I By Fund Common Stock 2006-09-12 4 A 0 119763 A 211499 I By Fund Common Stock 2006-09-12 4 A 0 408460 A 408460 I By Fund Common Stock 2006-09-12 4 A 0 532768 A 941228 I By Fund Common Stock 2006-09-12 4 A 0 10211 A 10211 I By Fund Common Stock 2006-09-12 4 A 0 13319 A 23530 I By Fund Stock Option (Right to Buy) 15.04 2006-09-12 4 A 0 28125 A 2016-09-12 Common Stock 28125 28125 D Stock Option (Right to Buy) 15.04 2006-09-12 4 A 0 1875 A 2016-09-12 Common Stock 1875 30000 D Reflects a 1-for-4 reverse stock split, which became effective on September 12, 2006. Received in exchange for 467,148 shares of Infinity Discovery, Inc. ("IPI") Series A Preferred Stock in connection with the merger (the "Merger") of IPI into Infinity Pharmaceuticals, Inc., formerly known as Discovery Partners International, Inc., based on a conversion ratio of 0.78550 (before giving effect to the reverse stock split referenced in footnote 1). The Series A Preferred Stock had no expiration date. Securities held of record by Venrock Associates, a limited partnership of which Anthony B. Evnin is a General Partner. Mr. Evnin disclaims beneficial ownership of these securities except to the extent of his pro-rata interest. Received in exchange for 479,563 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 0.99894 (before giving effect to the reverse stock split referenced in footnote 1). The Series B Preferred Stock had no expiration date. Received in exchange for 2,080,000 shares of IPI Series A Preferred Stock in connection with the Merger based on a conversion ratio of 0.78550 (before giving effect to the reverse stock split referenced in footnote 1). The Series A Preferred Stock had no expiration date. Securities held of record by Venrock Associates III, L.P., a limited partnership of which Venrock Management III LLC is the General Partner. Anthony B. Evnin is a Member of Venrock Management III LLC and disclaims beneficial ownership of these securities except to the extent of his pro-rata interest. Received in exchange for 2,133,334 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 0.99894 (before giving effect to the reverse stock split referenced in footnote 1). The Series B Preferred Stock had no expiration date. Received in exchange for 52,000 shares of IPI Series A Preferred Stock in connection with the Merger based on a conversion ratio of 0.78550 (before giving effect to the reverse stock split referenced in footnote 1). The Series A Preferred Stock had no expiration date. Securities held of record by Venrock Entrepreneurs Fund III, L.P., a limited partnership of which VEF Management III LLC is the General Partner. Anthony B. Evnin is a Member of VEF Management III LLC and disclaims beneficial ownership of these securities except to the extent of his pro-rata interest. Received in exchange for 53,333 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 0.99894 (before giving effect to the reverse stock split referenced in footnote 1). The Series B Preferred Stock had no expiration date. The Stock Option vests as to 9,375 of the shares on the first anniversary of the grant date, which grant date was September 12, 2006, and the remainder in quarterly installments of 2,343 shares beginning at the end of the first quarter thereafter, provided that the holder continues to serve as a Director. Not applicable. The Stock Option vests in quarterly installments of 468 shares beginning at the end of the first quarter after the date of grant, which grant date was September 12, 2006, provided that the holder continues to serve as the Chairman of the Compensation Committee of the Board of Directors. Anthony B. Evnin 2006-09-14